386 related articles for article (PubMed ID: 28415571)
1. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
[TBL] [Abstract][Full Text] [Related]
2. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
5. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
6. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
[TBL] [Abstract][Full Text] [Related]
8. Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Sun C; Zhou X; Zou ZJ; Guo HF; Li JY; Qiao C
Chin Med J (Engl); 2016 Aug; 129(15):1778-83. PubMed ID: 27453224
[TBL] [Abstract][Full Text] [Related]
9. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
10. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
11. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
[TBL] [Abstract][Full Text] [Related]
14. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
16. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
[TBL] [Abstract][Full Text] [Related]
17. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
18. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
[TBL] [Abstract][Full Text] [Related]
19. CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
Zini R; Guglielmelli P; Pietra D; Rumi E; Rossi C; Rontauroli S; Genovese E; Fanelli T; Calabresi L; Bianchi E; Salati S; Cazzola M; Tagliafico E; Vannucchi AM; Manfredini R;
Blood Cancer J; 2017 Dec; 7(12):638. PubMed ID: 29217833
[TBL] [Abstract][Full Text] [Related]
20. Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
Rattarittamrong E; Tantiworawit A; Kumpunya N; Wongtagan O; Tongphung R; Phusua A; Chai-Adisaksopha C; Hantrakool S; Rattanathammethee T; Norasetthada L; Charoenkwan P; Lekawanvijit S
Hematology; 2018 Oct; 23(9):613-619. PubMed ID: 29521158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
